Medical Device Extract Preparation and Testing: Standards, Methods, and Technical Requirements

Medical device extract preparation and testing is a cornerstone of biocompatibility evaluation and chemical characterization under the ISO 10993 series of standards. By exposing device materials to defined extraction vehicles under controlled conditions, laboratories can identify extractables and leachables that may migrate into patients during clinical use. This technical guide covers sample selection, extraction ratios, vehicle choice, analytical methods, and practical applications for manufacturers seeking regulatory compliance.

Technical Overview

Extract preparation is the controlled process of immersing or perfusing a medical device, a device component, or a material coupon in a defined extraction vehicle under specified temperature, duration, and surface-area-to-volume conditions. The resulting test extract serves two fundamental purposes in device safety evaluation: it acts as a dosing solution for biological assays such as cytotoxicity, sensitization, irritation, and acute systemic toxicity, and it provides an analytical sample for chemical characterization of extractables and leachables.

The governing framework is built on the ISO 10993 series of standards. ISO 10993-12 defines sample selection, surface area determination, extraction ratios, extraction vehicles, and extraction conditions. ISO 10993-18 addresses the chemical characterization of device materials, while ISO 10993-17 provides the framework for toxicological risk assessment of identified compounds. ISO 10993-1 situates all extraction-based testing within an overall biological evaluation and risk management process aligned with ISO 14971. In China, the GB/T 16886 series adopts the ISO 10993 standards, and GB/T 14233.1 specifies chemical analysis methods for infusion, transfusion, and injection equipment. ASTM F619 provides additional guidance for the extraction of medical plastics, and EN ISO 10993 versions apply within European regulatory frameworks.

Proper extract preparation is critical because every downstream biological and chemical conclusion depends on the representativeness of the extract. Under-extraction may conceal hazardous substances, while over-aggressive extraction may generate artifacts that do not reflect real patient exposure. A scientifically justified extraction design is therefore the foundation of a defensible biological evaluation file.

Testing Samples

Samples for extraction studies may be finished sterile devices, subassemblies, representative components, or material coupons cut from sheets or molded plaques. Whenever possible, samples should reflect the final product in its as-manufactured, sterilized, and packaged condition, since processing aids, sterilization residues, and packaging migrants can all contribute to the extract profile.

Polymeric and Plastic Devices

Polymeric materials such as PVC, polyethylene, polypropylene, polycarbonate, polyurethane, and silicone elastomers dominate device construction and represent the largest category of extraction samples. Typical extractables include plasticizers, antioxidant additives, residual monomers, oligomers, lubricants, and colorants.

Metallic Implants and Instruments

Stainless steels, titanium alloys, and cobalt-chromium alloys are evaluated for the release of elemental impurities such as nickel, chromium, cobalt, vanadium, and aluminum. Extraction studies on metals focus heavily on ion leaching into polar vehicles.

Elastomeric and Rubber Components

Seals, gaskets, septa, and tubing made from natural or synthetic elastomers may release vulcanization accelerators, antioxidants, peroxide decomposition products, and nitrosamines, all of which require targeted analytical screening.

Ceramics, Composites, and Coated Surfaces

Biodegradable and Combination Products

Absorbable materials such as PLA and PLGA, along with drug-device combination products, require extraction designs that account for degradation products and interactions between the drug, the device, and the extraction vehicle.

Testing Items

Physicochemical Indicators of Extracts

• pH change or acidity/alkalinity of the extract versus the blank vehicle
• Non-volatile residue (evaporation residue) as a measure of total migrated substances
• Reducing substances, commonly expressed as potassium permanganate consumption
• Heavy metals content, reported as lead equivalents or as individual elements
• Ultraviolet absorbance at specified wavelengths as a screening indicator
• Turbidity and coloration of the extract

Elemental Impurities

Individual elemental targets typically include lead, cadmium, mercury, arsenic, chromium, nickel, cobalt, vanadium, aluminum, copper, and tin, with method sensitivity aligned to toxicological reference doses established under ISO 10993-17.

Organic Extractables and Target Analytes

• Volatile organic compounds, including residual solvents and monomers such as styrene, methyl methacrylate, and acrylonitrile
• Semi-volatile compounds, including plasticizers such as phthalate esters, antioxidant additives such as hindered phenols and phosphite stabilizers, and vulcanization agents
• Non-volatile compounds, including oligomers, waxes, and polymeric additives
• Degradation products, nitrosamines, polycyclic aromatic hydrocarbons from carbon-containing materials, and dye or pigment migrants

Biological Assays Performed Using Extracts

Extracts are the dosing material for the extract-based cytotoxicity test of ISO 10993-5, sensitization tests under ISO 10993-10, irritation and intracutaneous reactivity tests under ISO 10993-23, acute systemic toxicity under ISO 10993-11, hemocompatibility screening, and genotoxicity assays under ISO 10993-3.

Testing Methods

Extraction Vehicle Selection

Vehicle selection mirrors the polarity range of potential extractables and the requirements of the downstream assay. A polar and a non-polar vehicle are generally used in parallel.

• Polar vehicles: purified water, 0.9% sodium chloride solution, and culture medium without or with serum (for cytotoxicity)
• Non-polar vehicles: vegetable oils such as cottonseed or sesame oil, typically for in vivo assays
• Additional vehicles when justified: ethanol/water mixtures, ethanol/saline mixtures, polyethylene glycol 400, and dimethyl sulfoxide

Extraction Ratios and Surface Area Determination

ISO 10993-12 prescribes standardized surface-area-to-volume ratios so that extract concentrations are reproducible and clinically interpretable.

• Materials with a thickness of 0.5 mm or less: 6 cm² of total surface area per mL of extraction vehicle
• Materials thicker than 0.5 mm: 3 cm²/mL
• Irregularly shaped solid devices: 0.1 to 0.2 g of material per mL of vehicle, or an equivalent surface-area basis of 6 cm²/mL
• Hollow devices such as tubing, catheters, and containers: the lumen surface is included in the total surface area calculation

Both contacting and non-contacting surfaces must be considered when non-contacting surfaces could contaminate the patient-use pathway. All ratio decisions and surface area calculations must be documented in the study rationale.

Extraction Temperature and Duration

Extraction conditions should simulate or moderately exaggerate clinical exposure without altering the material or degrading the vehicle. Commonly applied standard conditions include:

• 37 °C for 72 hours, simulating physiological exposure
• 50 °C for 72 hours, for moderately exaggerated extraction
• 70 °C for 24 hours, for accelerated extraction of stable materials
• 121 °C for 1 to 2 hours, only for materials that withstand autoclave temperatures

Static extraction, gentle agitation, or dynamic perfusion of fluid pathways may be selected to represent the actual use conditions of the device. Glass or inert containers with lined caps are used to minimize background contamination, and reagent blanks are processed in parallel.

Analytical Instrumentation for Extract Characterization

• Headspace gas chromatography-mass spectrometry for volatile organic compounds
• Gas chromatography-mass spectrometry for semi-volatile organic compounds
• Liquid chromatography-tandem mass spectrometry and HPLC with UV, diode-array, or fluorescence detection for non-volatile and thermally labile compounds
• Inductively coupled plasma mass spectrometry or optical emission spectrometry for elemental impurities
• Ion chromatography, total organic carbon analysis, UV-Vis spectrophotometry, and FTIR spectroscopy as supporting techniques

Unknown peaks are provisionally identified by spectral library matching and confirmed with reference standards where the estimated quantity approaches safety-relevant thresholds.

Data Evaluation and Safety Thresholds

Under ISO 10993-18, each reported extractable is compared against an analytical evaluation threshold derived from toxicological safety concern thresholds and device exposure assumptions in accordance with ISO 10993-17. Compounds exceeding the evaluation threshold undergo toxicological risk assessment, while compounds below the threshold are documented and excluded from further evaluation. This threshold-based approach keeps chemical characterization proportionate to actual patient risk.

Method Validation and Quality Control

Quantitative methods are validated for specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. Extraction reproducibility is verified through replicate preparations, certified reference materials support elemental analysis where available, and stability of extracts between preparation and analysis is demonstrated or justified. Accredited third-party laboratories routinely apply these controls within ISO/IEC 17025-aligned quality systems.

Applications

Extract preparation and testing data support a wide range of regulatory and engineering objectives:

• Biocompatibility dossiers for market authorization submissions across major jurisdictions, where chemical characterization and biological test data form a unified evaluation file
• Verification of design changes, material substitutions, supplier changes, or manufacturing process changes that could alter the extract profile
• Evaluation of sterilization effects, including ethylene oxide residuals under ISO 10993-7 and radiation-induced degradation products
• Compatibility assessment for drug-device combination products, fluid delivery systems, and primary packaging interactions
• Supplier qualification and incoming material control programs for high-risk components
• Inputs to the biological evaluation plan and report required by ISO 10993-1 and the risk management file under ISO 14971

FAQ

What is the difference between extractables and leachables?

Extractables are compounds released from a device under exaggerated laboratory conditions, such as elevated temperature or stronger solvents, and they define the potential scope of migration. Leachables are the compounds that actually migrate under real clinical conditions of use. Extractables studies are typically performed first to establish a comprehensive compound inventory, followed by targeted leachables confirmation where warranted.

Why are both polar and non-polar extraction vehicles required?

Device materials contain substances spanning the full polarity range. Aqueous vehicles efficiently extract ionic species, catalyst residues, and polar organics, while non-polar vehicles extract lipophilic additives such as plasticizers and oils. Using both vehicle classes ensures that neither class of potential toxicant is missed, and it matches the physiological reality of both aqueous tissue contact and lipid contact scenarios.

Which extraction ratio applies to an irregularly shaped device?

When the surface area of an irregular device cannot be measured reliably, ISO 10993-12 permits a mass-based ratio of 0.1 to 0.2 g of material per mL of vehicle. Alternatively, a surface-area equivalent of 6 cm²/mL can be used if the geometry can be reasonably approximated. Whichever basis is selected, the calculation must be documented.

How are extraction temperature and time selected?

Conditions are chosen to simulate clinical exposure where feasible and to moderately exaggerate it where sensitivity is needed, while remaining below temperatures that would melt, soften, or thermally degrade the material or decompose the extraction vehicle. For thermally sensitive materials, 37 °C for 72 hours is generally appropriate; more aggressive conditions require a documented justification.

How quickly should extracts be tested after preparation?

Extracts should be tested as soon as possible after preparation, ideally within 24 hours for biological assays. If storage is unavoidable, extracts are held in inert containers protected from light and heat, and the stability of target analytes during the storage period must be demonstrated or justified.

What is the analytical evaluation threshold?

The analytical evaluation threshold is the concentration in the extract above which an identified compound requires toxicological review. It is calculated from a safety concern threshold, the device exposure scenario, and a correction factor for analytical uncertainty. The concept, formalized in ISO 10993-18 with toxicological input from ISO 10993-17, ensures analytical effort focuses on compounds with genuine safety relevance.

Can the same extract be used for chemical characterization and biological assays?

In most cases, no. Chemical characterization frequently uses exhaustive or exaggerated extraction with organic solvents to maximize compound recovery, whereas biological assays require physiologically compatible vehicles such as culture medium, saline, or vegetable oil. Separate extractions, each designed for its intended purpose, are the standard practice.